Cortexyme Inc (the company was transformed to Quince Therapeutics (QNCX)) (CRTX) Reports Q2 2022 Financial Results
Cortexyme Inc (the company was transformed to Quince Therapeutics (QNCX)) (CRTX) announced its financial results for the period ending Q2 2022.
Key Financial Highlights:
Revenue: $120 million
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: $120 million
targeting platform that allows it to deliver systemically administered small molecules, peptides or large molecules directly to the site of disease or injury, thereby potentially increasing the therapeutic effect while minimizing off-target effects. Novosteo has not yet generated revenues and Novosteo’s lead candidate, NOV004, is expected to enter Phase 1 clinical trials in 2023
📊 Key Financial Metrics:
Metric
Value
Revenue
$120 million
Cash
$120 million
💼 Business Developments:
Partnership
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available
Structured Data:
Company Name: Cortexyme Inc (the company was transformed to Quince Therapeutics (QNCX))
📋 CORTEXYME, INC. (CRTX) - Financial Results
Filing Date: 2022-05-12
Accepted: 2022-05-12 17:12:57
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics:
💼 Business Developments:
Structured Data: